https://www.drugs.com/tips/semaglutide-patient-tips
The results claimed here seem to be a bit on the sensational side, so I would not necessarily accept them at face value. I have seen several reports that show the weight loss aspect but did not monitor sugar levels, so I am also at a loss as to who did those tests, and where they are reported.
I must reiterate the recent warning that the -glutides in general are associated with thyroid cancer, as had been evidenced by a poster on this site who has contracted that condition shortly after commencing treatment.
This seems to describe a trial for glucose, but please note thst the result reported is shown as Estimated, and was of the order of only 1.5 mmol/l drop post prandial, which is about the same as metformin.
https://pubmed.ncbi.nlm.nih.gov/28941314/
They also claim that the first phase insulin response is improved but there seems to be no test carried out to verify that (i.e. insulin clamp / IVGTT) and also they simultaneously claim that the drug slows gastric emptying, which again will actually prevent the first phase response which is a reaction to a step change in glucose levels and is not testable by oral methods. This trial was performed and paid for by the drug manufacturer, so it seems to be very poor quality evidence.
It is primarily being generally prescribed for weight loss / obesity cure, and the glucose lowering aspects are probably due to weight loss rather than any magic being done by the drug. The results quoted that I see are that post prandial levels dropped by an average of 1 mmol/; at the 1 hour mark, and took 5 hours to drop back to fasting level. The numbers show that at least one respondent has up to 1.4 mmol/l drop but the lower figure of 0,24 shows that some had hardly any improvement, They used Area Under the Curve technique to obsfurcate the result where a mathematical mean or average calculation may give a worse result.
https://pubmed.ncbi.nlm.nih.gov/28941314/#&gid=article-figures&pid=figure-1-uid-0